Solid Biosciences Inc. disclosed a material event
SEC 8-KRead source ↗
Solid Biosciences Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders0 buying, 7 selling0 purchases and 29 sales by directors and officers, last 12 monthsInsider trades
- Funds97 adding, 62 cuttingOf 41 active managers that changed their stake, 20 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 19% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Solid Biosciences Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 79% and a beta of 2.1 against the S&P 500.
- Heavily shorted. 13.0% of the shares available to trade are sold short (7.9 days of average volume to cover).
Latest results
- Earnings per share
- -$0.38 against an average estimate of -$0.47: beat by 18.9%
- Share reaction
- +43.0% in the first session after the results on March 6, 2026, against -0.4% for the S&P 500
- Next report
- November 2, 2026; average EPS estimate -$0.41
Price chart
- 1 day-3.2%
- 1 week+3.3%
- 1 month-12.4%
- This year+6.4%
- 1 year+11.3%
- 5 years-83.0%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- March 6, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Announcement
No model value for Solid Biosciences Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$1.76 | +12% | — | 0% |
| Next | −$1.71 | +3% | $9m | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −10.3% on 90 days ago. In the last 30 days, 0 analysts raised Solid Biosciences Inc.'s forecast and 1 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$1.96 | −$1.96 |
| 60 days ago | −$1.77 | −$1.75 |
| 30 days ago | −$1.76 | −$1.73 |
| 7 days ago | −$1.76 | −$1.70 |
| Now | −$1.76 | −$1.71 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.47 | −$0.38 | +18.9% |
| Dec 2025 | −$0.52 | −$0.53 | −1.8% |
| Sept 2025 | −$0.44 | −$0.48 | −8.9% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 13.0% of tradable shares
- Days to cover
- 7.88 at average volume
- Short interest, 1 month
- −28% to October 15, 2026
- Held by institutions
- — of shares
- Held by insiders
- 0.7% of shares
- Employees
- 121 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| SLDB | −77% | −80% | +14% | −35% | +41% | +6% |
| Industry peers (median) | −35% | −56% | −18% | −28% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| SLDB | 8% | 42% | 42% | 50% | 50% | 55% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| SLDB | −84% | −80% | −76% | −73% | −61% | −51% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since January 26, 2018: 100% from September 20, 2018 to October 27, 2023. Getting back needed a 40932% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $3.93 – $11.15
- From 52-week high
- −46.2%
- vs 50-day average
- −22.6%
- vs 200-day average
- −21.7%
- Volatility (1 year)
- 79%
- Beta vs S&P 500
- 2.14
Share price after results
- Next day
- 5 up, 7 down typical move ±21.4%
- After a week
- 5 up, 7 down typical move ±20.6%
- After a month
- 5 up, 7 down typical move ±20.8%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| March 6, 2026 | +43.0% | −0.4% | +30.3% | +38.0% |
| November 3, 2025 | −18.3% | −1.0% | −23.0% | −3.7% |
| February 18, 2025 | +60.5% | +0.5% | +31.3% | +19.6% |
| January 8, 2024 | +45.6% | +1.3% | +44.7% | +31.1% |
| January 9, 2023 | +1.7% | +0.6% | +22.2% | +25.1% |
| August 11, 2022 | +6.5% | +1.7% | +7.9% | −12.8% |
| April 27, 2022 | −24.1% | +2.8% | −27.0% | −33.8% |
| January 10, 2022 | −1.3% | +0.8% | −6.3% | −22.2% |
| August 16, 2021 | −3.0% | −0.4% | −3.0% | −1.1% |
| May 14, 2021 | −20.0% | +1.3% | −9.5% | −9.2% |
| March 15, 2021 | −32.5% | +0.5% | −40.5% | −44.3% |
| November 5, 2020 | −0.6% | +1.9% | −1.9% | +8.3% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $1.1B
- Institutions reporting
- 156
- Shares held vs prior quarter
- ▲ 14.7%
- Positions opened / closed
- 40 / 24
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| RA Capital Management, L.P. | $120M | 12.0M | 10.5% | ▲ 28.9% |
| Perceptive Advisors LLC | $119M | 11.9M | 10.4% | 0.0% |
| Bain Capital Life Sciences Investors, LLC | $98M | 9.8M | 8.6% | 0.0% |
| Siren, L.L.C. | $76.8M | 7.7M | 6.7% | 0.0% |
| Blackrock, Inc. | $69.3M | 6.9M | 6.1% | ▲ 39.8% |
| FMR LLC | $68.7M | 6.9M | 6.0% | ▲ 90.7% |
| Armistice Capital, LLC | $42.7M | 4.3M | 3.7% | ▲ 33.7% |
| State Street Corp | $41.7M | 4.2M | 3.6% | ▲ 271.0% |
| Jupiter Topco LLC | $40.4M | 4.0M | 3.5% | — |
| Vanguard Capital Management LLC | $40.1M | 4.0M | 3.5% | ▲ 49.9% |
| RTW Investments, LP | $38.9M | 3.9M | 3.4% | New |
| Deep Track Capital, LP | $35.6M | 3.6M | 3.1% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Solid Biosciences Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $2.7M 29 trades by 7 insiders · 99% under pre-set plans
Net ▼ $2.7M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Brooks Gabriel Chief Medical Officer | October 19, 2026 | Sell pre-set plan | 4,374 | $5.62 | $24,582 |
| Tan Kevin CFO & Treasurer | February 18, 2026 | Sell pre-set plan | 5,404 | $5.82 | $31,451 |
| Brooks Gabriel Chief Medical Officer | February 18, 2026 | Sell pre-set plan | 0 | $5.82 | $0 |
| Howton David T Chief Operating Officer | February 18, 2026 | Sell pre-set plan | 7,469 | $5.82 | $43,470 |
| Herzich Paul Chief Technology Officer | February 18, 2026 | Sell pre-set plan | 3,616 | $5.82 | $21,045 |
| Ganot Ilan Director | February 18, 2026 | Sell pre-set plan | 2,658 | $5.82 | $15,470 |
| Hanrahan Jessie Chief Regulatory Officer | February 18, 2026 | Sell pre-set plan | 4,134 | $5.82 | $24,060 |
| Cumbo Alexander President and CEO | February 18, 2026 | Sell pre-set plan | 16,644 | $5.82 | $96,868 |
| Herzich Paul Chief Technology Officer | February 4, 2026 | Sell pre-set plan | 10,905 | $6.44 | $70,228 |
| Hanrahan Jessie Chief Regulatory Officer | February 4, 2026 | Sell pre-set plan | 12,348 | $6.44 | $79,521 |
| Brooks Gabriel Chief Medical Officer | February 4, 2026 | Sell pre-set plan | 12,616 | $6.44 | $81,247 |
| Tan Kevin CFO & Treasurer | February 4, 2026 | Sell pre-set plan | 14,783 | $6.44 | $95,203 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- March 6, 2026
- November 3, 2025
- February 18, 2025
- January 8, 2024
- January 9, 2023
- August 11, 2022
Recent SEC filings
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 10-Q Quarterly report
- DEF 14A Proxy statement
- 8-K Current report
- S-3 S-3
- S-3 S-3
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Solid Biosciences Inc. in brief
- What does Solid Biosciences Inc. do?
- Solid Biosciences Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Solid Biosciences Inc.'s stock ticker?
- Solid Biosciences Inc. trades under the ticker SLDB on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Solid Biosciences Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are RA Capital Management, L.P., Perceptive Advisors LLC and Bain Capital Life Sciences Investors, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Solid Biosciences Inc. stock?
- Over the last 12 months, Solid Biosciences Inc.'s directors and officers reported 0 open-market purchases and 29 sales on Form 4. The insider trading page charts every trade.
Follow research on Solid Biosciences Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.